This sets the scene for negotiating a few licencing deals on Matt's terms....:
"Botanix is actively working with a number of pharmaceutical partners who are using the PermetrexTM delivery system to formulate their proprietary actives, into new and more effective formulations for clinical development and the Company welcomes new collaborations."
Ann: Permetrex Outperforms Other CBD Topical Products, page-11
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $391.8K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 160000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 11013 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
